icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
J&J New HCV Nucleotides - AL-335 & AL-516
  .......AL-516 is a novel guanosine nucleotide analog.....with a highly favorable in vitro safety and resistance profile .......compound is advancing towards Phase 1 clinical studies in 2015 .......AL-335, a novel uridine base nucleotide analog .......demonstrates an in vitro antiviral profile that suggests it has the potential to be an important component of IFN-free combination therapy.
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma's HCV Nukes - (10/15/14)
"Alios' most valuable assets may the two early-stage nucs it has in development for hepatitis C. Earlier this month, the biotech touted the preclinical profile of its lead hep C candidate, AL-335, announcing plans to roll it into Phase I in the fourth quarter of this year. Alios' second hep C prospect, AL-516, is on schedule to begin human trials in 2015"
Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C - (10/15/14)
"The AASLD/EASL poster presented preclinical data of AL-335, a novel uridine nucleotide analog. The goal of the current study was to evaluate the antiviral activity and selectivity of AL-335. Results from the study showed that AL-335 demonstrates potent inhibition of HCV in the cell-based replicon assay across genotypes.....has a long in vivo half-life.....AL-335 and AL-516 are nucleotide analog polymerase inhibitors, a class of compounds that has emerged as a key component of interferon-free combination regimens used in the treatment of chronic hepatitis C"
AASLD/EASL NY HCV Special Conference: Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (10/15/14)
Analysis of AL-335, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the HCV Subgenomic Replicon System
AASLD 2014
Reported by Jules Levin
Tan, H., Shaw, K., Prhavc, M., Williams, C., Wang, G., Beigelman, L., Smith, D.B., Blatt, L.M., Symons, J.A.
Alios BioPharma, Inc., South San Francisco, CA, USA







Preclinical Characterization of AL-516, a Potent Guanosine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C
AASLD 2014
Reported by Jules Levin
Hua Tan, Kenneth Shaw, Andreas Jekle, Jerome Deval, Zhinan Jin, Amy Fung, Yuen Tam, Lawrence M. Blatt, Sushmita M. Chanda, Guangyi Wang, Natalia Dyatkina, Marija Prhavc, Caroline Williams, Vladimir Serebryany, Qingling Zhang, Julian A. Symons, Leonid Beigelman and David B. Smith* Alios BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, CA, USA.